Dynavax Reports First Quarter 2014 Financial Results
May 05 2014 - 9:00AM
Marketwired
Dynavax Reports First Quarter 2014 Financial Results
BERKELEY, CA--(Marketwired - May 5, 2014) - Dynavax Technologies
Corporation (NASDAQ: DVAX) today reported financial results for the
first quarter ended March 31, 2014. The Company had $177.7 million
in cash, cash equivalents and marketable securities as of March 31,
2014.
For the quarter ended March 31, 2014, Dynavax reported total
revenues of $3.5 million compared to $2.1 million for the first
quarter of 2013. This increase primarily relates to the recognition
of revenue under our collaboration agreement with AstraZeneca.
General and administrative expenses were $4.2 million for the
quarter ended March 31, 2014 compared to $8.8 million for the first
quarter of 2013. The 2013 three month period includes non-recurring
cash and non-cash stock-based severance costs of $2.5 million.
Excluding these non-recurring organizational transition costs,
general and administrative expenses decreased by 34% in the first
quarter of 2014 compared to the first quarter of 2013.
Research and development expenses were $13.2 million for the
quarter ended March 31, 2014 compared to $14.2 million for the
first quarter of 2013. This decrease was primarily due to higher
severance expenses, including non-cash stock-based compensation
charges, in the 2013 period.
About Dynavax
Dynavax, a clinical-stage biopharmaceutical company, discovers
and develops novel vaccines and therapeutics in the areas of
infectious and inflammatory diseases and oncology. Dynavax's lead
product candidate is HEPLISAV, a Phase 3 investigational adult
hepatitis B vaccine. For more information visit
www.dynavax.com.
|
DYNAVAX TECHNOLOGIES CORPORATION |
CONSOLIDATED STATEMENTS OF OPERATIONS |
(In thousands, except per share amounts) |
(Unaudited) |
|
|
|
Three Months Ended March 31, |
|
|
|
2014 |
|
|
2013 |
|
Revenues: |
|
|
|
|
|
|
|
|
|
Collaboration revenue |
|
$ |
2,373 |
|
|
$ |
883 |
|
|
Grant
revenue |
|
|
1,125 |
|
|
|
760 |
|
|
Service and license revenue |
|
|
- |
|
|
|
442 |
|
Total revenues |
|
|
3,498 |
|
|
|
2,085 |
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
Research and development |
|
|
13,231 |
|
|
|
14,164 |
|
|
General and administrative |
|
|
4,157 |
|
|
|
8,800 |
|
|
Unoccupied facility expense |
|
|
77 |
|
|
|
- |
|
Total operating expenses |
|
|
17,465 |
|
|
|
22,964 |
|
|
|
|
|
|
|
|
|
|
Loss from operations |
|
|
(13,967 |
) |
|
|
(20,879 |
) |
|
|
|
|
|
|
|
|
|
Interest income |
|
|
65 |
|
|
|
72 |
|
Interest expense |
|
|
- |
|
|
|
(32 |
) |
Other income |
|
|
62 |
|
|
|
14 |
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(13,840 |
) |
|
$ |
(20,825 |
) |
|
|
|
|
|
|
|
|
|
Basic and diluted net loss per share |
|
$ |
(0.05 |
) |
|
$ |
(0.11 |
) |
|
|
|
|
|
|
|
|
|
Shares used to compute basic and diluted net loss per
share |
|
|
262,826 |
|
|
|
182,847 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DYNAVAX
TECHNOLOGIES CORPORATION |
SELECTED
BALANCE SHEET DATA |
(In
thousands) |
(Unaudited) |
|
|
|
|
|
|
|
|
March 31, |
|
December 31, |
|
|
2014 |
|
2013 |
Assets |
|
|
|
|
|
|
|
Cash,
cash equivalents and marketable securities |
|
$ |
177,679 |
|
$ |
189,376 |
|
Property and equipment, net |
|
|
8,584 |
|
|
8,706 |
|
Goodwill |
|
|
2,576 |
|
|
2,579 |
|
Other
assets |
|
|
4,746 |
|
|
3,961 |
Total assets |
|
$ |
193,585 |
|
$ |
204,622 |
|
|
|
|
|
|
|
Liabilities and stockholders'equity |
|
|
|
|
|
|
|
Deferred revenues |
|
$ |
10,334 |
|
$ |
7,298 |
|
Other
liabilities |
|
|
9,398 |
|
|
11,030 |
|
Total
liabilities |
|
|
19,732 |
|
|
18,328 |
|
Stockholders' equity |
|
|
173,853 |
|
|
186,294 |
Total liabilities and stockholders' equity |
|
$ |
193,585 |
|
$ |
204,622 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contact: Michael Ostrach Chief Business and Principal Financial
Officer 510-665-7257 Email
Contact
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024